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Abstract
Background: In addition to their antimicrobial activity, antibiotics modulate cellular host defence.
Granulocyte-colony stimulating factor (G-CSF) is also a well known immunomodulator; however
little is known about the interactions of G-CSF with antibiotics. We investigated in septic rats the
effects of two antibiotic combinations with G-CSF.
Methods: In two clinic modelling randomised trials (CMRTs), male Wistar rats were anesthetized,
given antibiotic prophylaxis, had a laparotomy with peritoneal contamination and infection (PCI),
and were randomly assigned (n = 18 rats/group) to: 1) PCI only; 2) PCI+antibiotic; and, 3)
PCI+antibiotic+G-CSF prophylaxis (20 µg/kg, three times). This sequence was conducted first with
10 mg/kg coamoxiclav, and then with ceftriaxone/metronidazole (Cef/met, 10/3 mg/kg). In
additional animals, the blood cell count, migration and superoxide production of PMNs, systemic
TNF-α and liver cytokine mRNA expression levels were determined.
Results: Only the combination coamoxiclav plus G-CSF improved the survival rate (82 vs. 44%, p
< 0.001). Improved survival with this combination was accompanied by normalised antimicrobial
PMN migratory activity and superoxide production, along with normalised systemic TNF-α levels
and a reduced expression of TNF-α and IL-1 in the liver.
Conclusion:  There are substantial differences in the interaction of antibiotics with G-CSF.
Therefore, the selection of the antibiotic for combination with G-CSF in sepsis treatment should
be guided not only by the bacteria to be eliminated, but also by the effects on antimicrobial
functions of PMNs and the cytokine response.
Background
Source control and antibiotic treatment are the mainstays
in the treatment of infectious disease. Interestingly, anti-
biotics not only directly reduce bacterial growth; they also
modulate cellular host defence, especially the antimicro-
bial functions of monocytes and granulocytes [1]. Some
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antibiotics enhance cellular host defence mechanisms,
but others have adverse effects. How these alterations
occur remains poorly understood, but cytokines and
chemokines are throught to be important regulators of
antimicrobial functions [2].
Granulocyte colony-stimulating factor (G-CSF) is a glyco-
peptide which stimulates the granulocyte lineage and
stem cells. G-CSF also suppresses release of pro-inflamma-
tory cytokines such as TNF-α by macrophages [3]. G-CSF
stimulates neutrophil recruitment and chemotaxis [4],
increases phagocytosis of bacteria and production of free
radicals [5], and retards normal granulocyte apoptosis [6].
The beneficial effects of G-CSF have been demonstrated in
different animal models of sepsis [7-12]. In clinical trials,
recombinant G-CSF (filgrastim) proved to be effective in
diabetic foot ulcers [13] and high-risk febrile neutropenia
[14], but not for community acquired pneumonia [15].
To evaluate the interaction of different antibiotics with G-
CSF, we used clinic modelling randomised trials
(CMRTs). The inclusion of an i.v. antibiotic prophylaxis is
one important feature of CMRTs for modeling clinical
complexity. Others include appropriate use of anaesthe-
sia, volume loading, laparotomy, peritoneal contamina-
tion and infection with human stool bacteria (PCI),
suitable postoperative analgesia, and complicating risk
factors such as hypothermia and blood loss which we
have assessed previously [11,16]. Furthermore it was vali-
dated and confirmed extensively by our group in terms of
microbiologic characterization and reproducibility, as
shown by dose-mortality relationship [17]. In addition
characteristics of randomised clinical trials such as sample
size calculation, randomization, double-blind design,
analysis of morbidity, intent to treat analysis and ade-
quate statistics are included in CMRTs. CMRT characteris-
tics are summarised in a Table [see Additional file 1].
Using this model, we have evaluated cephalosporins,
aminoglycosides, fluoro-quinolones, and carbapenemes
in combination with G-CSF. All antibiotics are routinely
used for clinical peritonitis treatment at our institution.
Interestingly, 7 antibiotic/G-CSF combinations improved
survival, but 4 others did not [12,17]. For combination,
one of the best antibiotics (coamoxiclav) and one of the
worst antibiotics (Cef/met) with regard to survival were
selected for further investigations analyzing PMN func-
tion and pro-inflammatory organ cytokine expression and
systemic concentrations. We hypothesised that positive
antibiotic/G-CSF interactions resulting in a reduced mor-
tality rate after sepsis depend on improved PMN function
and reduced pro-inflammatory organ cytokine expression
and reduced systemic cytokine levels.
Methods
The study was performed with permission of the animal
welfare committee in Giessen, Hessen, Germany. 179
male Wistar rats, 220–280 g (Charles River Wiga, Sulzfeld,
Germany) were used. They were given standard diet
(Altromin, Lage, Germany) and water ad libitum.
Protocol
Two independent trials were performed to analyse sur-
vival. Separate animals were used for cytokine and PMN
function analyses. At arrival, animals were assigned to
study groups by simple random permutation using ear
marks to: 1) peritoneal contamination and infection
(PCI) only; 2) PCI + antibiotic prophylaxis, and 3) PCI +
antibiotic + G-CSF prophylaxis (n = 18 rats/group). In the
first trial, 10 mg/kg coamoxiclav was given; and in the sec-
ond trial, ceftriaxone/metronidazole (Cef/met, 5/2 mg/
kg) was given. Liver samples for mRNA analysis were
taken from additional animals (3 rats/group) from all six
treatment groups. Blood cell parameters and PMN func-
tions were assessed in main group animals and in addi-
tion in the groups G-CSF only and PCI only (n = 9 rats/
group).
The rats were deprived of food 12 hours before surgery.
Appropriate animals received 20 µg/kg G-CSF (Filgrastim,
Amgen, Munich, Germany) or placebo (Ringer's solution)
as a subcutaneous injection at three times: 12 hours
before surgery and 12 and 36 hours after surgery (PCI).
This dose regimen was most effective as determined in
dose response curves with G-CSF in the rat PCI model
[12,17]. The other groups were given equal volumes of
placebo (Ringer's solution).
One hour before surgery, the animals were anaesthetised
with 0.08 mg/kg fentanyl and 4 mg/kg droperidol, given
intraperitoneally. In the analgo-sedated, spontaneously
breathing animals a tail vein was cannulated. Animals
received intravenous antibiotic prophylaxis (one hour
before and one hour after surgery) with coamoxiclav
(Glaxo Smith Kline, Munich, Germany), or with ceftriax-
one (Roche, Grenzach-Wylen, Germany) combined with
metronidazole (Serag-Wiessner, Naila, Germany).
Using an antiseptic technique, a 2-cm-long midline inci-
sion was performed and 1.5 ml/kg standardized human
stool inoculum (diluted 1:2.5 in Ringer's solution) was
injected into the pelvic region. The wound was closed in
two layers using an interrupted vicryl 3-0 suture.
Postoperative analgesia consisted of 20 mg/kg tramadol
(Mundipharm, Limburg, Germany) injected subcutane-
ously once daily. Postoperatively, ad libitum food and
water was provided. The animals were checked carefully at
least twice daily for mortality and clinical signs. When anBMC Infectious Diseases 2008, 8:55 http://www.biomedcentral.com/1471-2334/8/55
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animal appeared to be weak, it was kept separately from
the others to prevent cannibalism. Animals surviving
throughout the 120-hour observation period were sacri-
ficed by inhalation of CO2.
Blood cell parameters
Under fentanyl 0.08 mg/kg and droperidol 4 mg/kg nar-
cosis, 2000 I.E. heparin (Liquemin, Roche AG, Basel, Swit-
zerland) was given intravenously. Blood was withdrawn
by puncture of the retro-orbital venous plexus. The white
blood cell count (WBC) was determined in an automated
counter optimized for rat blood (Coulter Max-M, Krefeld,
Germany). Granulocytes were purified on a discontinu-
ous histopaque 1119/1077 gradient for 30 minutes at 700
× g at room temperature. The cells were washed with PBS
buffer on ice and contaminating erythrocytes were lysed
with distilled water for 30 seconds. Viability, purity, and
the cell number were determined by trypan-blue staining
and counting in a Neubauer chamber.
PMN antimicrobial functions
Migration of PMNs was analyzed in Boyden chambers as
described by Cates at al. [18]. Zymosan-activated fetal calf
serum (10%) was the stimulant. The number of PMNs
adhering to the filter on the side orientated towards the
chemoattractant was counted in 10 randomly selected
high-power fields (10 × ocular and 40 × objective). To
determine the chemotactic activity in the wells with stim-
uli, the basal migration of PMNs from untreated animals
without stimuli was set to 100%.
The production of superoxide anions was analyzed in a
cytochrome-C microplate assay using a modified method
from Mayo et al. [19]. Each test was performed in tripli-
cate. For stimulation the cells were incubated with 2 µM
PMA (phorbol 12-myristate 13-acetate). The nonspecific
O2
- production was determined by adding 10 µM superox-
ide dismutase.
TNF-α plasma levels
EDTA anti-coagulated blood was immediately centrifuged
and plasma was stored at -70°C until assayed. Cytokine
TNF-α concentration was quantified with rat-specific
ELISA kits (Biosource, Camarillo, CA, USA).
Cytokine mRNA expression
Rats were sacrificed with a lethal dose of fentanyl and
droperidol 24 hours after PCI. Pieces of excised liver
weighing about 100 mg were frozen in liquid nitrogen
and then stored at -70°C. RNA was extracted with RNA-
Clean kits (ASG, Heidelberg, Germany). Briefly, extracted
RNA was stabilized with 40 U/µl RNasin® (Promega, Mad-
ison, WI, USA). For semi-quantitative, competitive RT-
PCR, a multi-specific competitor fragment for rat
cytokines with the conditions published by Siegling et al.
[20] was used.
Before amplification of the cytokine TNF-α, the house-
keeping gene β-actin was amplified to check the efficiency
of the reverse transcriptase reaction. When needed a cor-
rection was included in order to start with the same
amount of c-DNA in each tube (cDNA equivalent of about
5 ng total RNA). The competitor fragment was diluted 1:4
in 3 dilution steps starting with 2 pg; if needed, a further
dilution step was included. After PCR the samples were
separated in a 1% agarose gel, stained with ethidium bro-
mide, digitalized and analyzed with the Gelscan Software
(BioSciTec, Marburg, Germany). For quantification, only
bands with similar intensity on the grey scale between the
competitor fragment and the cytokines were used.
Statistical analysis
Survival rates were analysed with the Chi-square test and
survival curves with the log rank tests. Cellular and
cytokine data were assessed by ANOVA analysis of vari-
ance. If significant results were obtained in the global test,
post hoc tests were performed with a Bonferroni correction.
All tests were performed using the SPSS statistic software
package [21]. Cytokine and functional data are presented
as means ± SEMs. P < 0.05 was considered statistically sig-
nificant.
Results
Mortality
One rat died during anaesthesia, but before PCI, in the
first trial in the G-CSF group; all other rats were included
into the analysis. There were no further complications
related to the perioperative injections or surgery. No rat
survived without antibiotic prophylaxis. Coamoxiclav
prophylaxis increased survival to 44% (8/18) and surviv-
ial further increased to 82% (14/17) when prophylactic
G-CSF was included (p < 0.001, Figure 1A).
In the Cef/met trial, survival of the antibiotic prophylaxis
group was 44% (8/18) which was nearly identical to the
39% (7/18) survival when Cef/met was combined with G-
CSF (Figure 1B).
Blood cell parameters
In rats without PCI, G-CSF administration doubled the
WBC to 22.7 ± 2.0 × 106 cells/ml and increased the PMN
fraction to 31 ± 3.5% (Table 1). The systemic white blood
cell count decreased and the PMN fraction increased 24
hours after PCI. In infected rats, there was no significant
changes in WBC count or PMN fraction with either antibi-
otic prophylaxis (coamoxiclav or Cef/met) alone or in
combination with G-CSF.BMC Infectious Diseases 2008, 8:55 http://www.biomedcentral.com/1471-2334/8/55
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Kaplan-Meier 120 h survival analysis of septic rats from two independent CMRTs Figure 1
Kaplan-Meier 120 h survival analysis of septic rats from two independent CMRTs. Each group included n = 18 rats. 
A) Rats with coamoxiclav prophylaxis (10 mg/kg), coamoxiclav plus G-CSF prophylaxis before PCI and PCI without antibiotic 
prophylaxis. Significant differences were found by the Log-Rank Test over all groups (p < 0.001, df = 2) and in paired compari-
son PCI only versus coamoxiclav and PCI versus coamoxiclav + G-CSF (p < 0.001), coamoxiclav versus coamoxiclav plus G-
CSF (p < 0.05) in the intent to treat analysis. B) Rats with ceftriaxone/metronidazole (Cef/met) prophylaxis (5/2 mg/kg), Cef/
met plus G-CSF prophylaxis before PCI and PCI without antibiotic prophylaxis.
A)  
0
20
40
60
80
100
0 30 60 90 120
Time of observation [h]
S
u
r
v
i
v
a
l
r
a
t
e
 
[
%
]
PCI
CoA
CoA + G-CSF
0
20
40
60
80
100
0
20
40
60
80
100
0 30 60 90 120
Time of observation [h]
S
u
r
v
i
v
a
l
r
a
t
e
 
[
%
]
PCI
CoA
CoA + G-CSF
Number at risk   
PCI only  18  18    0    0    0    0   
CoA    18  16  11    8    8    8 
CoA + G-CSF  17  17  14  14  14  14   
 B)   
0
20
40
60
80
100
0 30 60 90 120
Time of observation [h]
S
u
r
v
i
v
a
l
r
a
t
e
 
[
%
]
PCI
Cef/met
Cef/met + G-CSF
0
20
40
60
80
100
0 30 60 90 120 0 30 60 90 120
Time of observation [h]
S
u
r
v
i
v
a
l
r
a
t
e
 
[
%
]
PCI
Cef/met
Cef/met + G-CSF
Number at risk     
PCI only  18  12    0    0    0    0   
Cef/met  18  17  17  11    8    8 
Cef/met + G-CSF  18  18  14  10    8    7BMC Infectious Diseases 2008, 8:55 http://www.biomedcentral.com/1471-2334/8/55
Page 5 of 10
(page number not for citation purposes)
PMN antimicrobial functions
PMN purity was comparable in each cell preparation.
PMN antimicrobial functions, specifically migration and
superoxide anion formation, were depressed after PCI
(Figure 2). Compared to PCI alone, coamoxiclav prophy-
laxis (P < 0.05) and in combination with G-CSF (P < 0.01)
improved the migratory activity of PMNs to approxi-
mately the level of cells from naive animals. In contrast,
Cef/met alone or in combination with G-CSF did not sig-
nificantly improve PMN migration.
Superoxide anion formation was also depressed by PCI.
With each antibiotic alone, no significant restoration of
the superoxide production was observed. Only the combi-
nation coamoxiclav and G-CSF increased superoxide pro-
duction capacity significantly compared to PCI alone (P <
0.01).
Cytokine levels
Systemic protein levels of TNF-α were significantly
increased 24 hours after PCI in all infected groups (Figure
3). TNF-α plasma levels were already decreased compared
to PCI by an antibiotic prophylaxis with coamoxiclav or
with Cef/met (p < 0.05), whereby a further reduction was
obtained by the addition of G-CSF only in the coamoxi-
clav group (p < 0.05 versus coamoxiclav).
In liver biopsies, mRNA expression of TNF-α, IL-1, MIP-2
and IL-10 were elevated in the antibiotic prophylaxis
groups compared to uninfected controls with the excep-
tion MIP-2 after antibiotic prophylaxis (Figure 4). TNF-α
was further significantly reduced (P < 0.05) by the combi-
nation coamoxiclav plus G-CSF and tended to be reduced
by the prophylaxis Cef/met plus G-CSF (P = 0.11) (Figure
4A). A further reduction of the cytokine IL-1 was also
observed after prophylaxis with coamoxiclav plus G-CSF
but not in combination with the other antibiotic (Figure
4B). The MIP-2 and IL-10 levels were in combination with
both antibiotics plus G-CSF not different from uninfected
controls (Figure 4C and 4D).
Discussion
The cytokine G-CSF is a glycopeptide that antagonizes the
neutrophil depression associated with bone marrow
transplantation or sepsis [22,23]. Cef/met alone reduces
the mortality rate in rats with peritoneal contamination
and infection, but no additive effect was obtained by com-
bining it with G-CSF. Only the combination coamoxiclav
plus G-CSF was highly effective. This result is consistent
with a previous report [24].
No differences were observed in the white blood cell
count or PMN ratio after G-CSF prophylaxis in combina-
tion with the two antibiotics. The absolute number of the
white blood cells thus does not appear to be a crucial fac-
tor explaining the efficacy of various antibiotics in combi-
nation with G-CSF.
Antimicrobial PMN functions, namely the migratory
activity and superoxide production are differently regu-
lated. In obstetric patients without antibiotic treatment
reduced PMN migration was predictive for infections in
cases of preterm premature rupture of membranes [25].
From the literature it is known that G-CSF stimulates cel-
lular immune defence mechanisms and alters the cytokine
network. G-CSF induces the granulocyte recruitment and
enhances their function at the site of infection, e.g. perito-
neally. Especially the production of superoxide anions
could be normalized in septic animals by G-CSF treat-
ment [26], but these results did not explain the antibiotic
differences.
Unfortunately, only very few results are available assess-
ing the antimicrobial activity and interaction of G-CSF
with different antibiotics. Beneficial effects of G-CSF in
combination with fluoro-quinolones such as ofloxacin on
the antimicrobial functions were reported [27]. With the
antibiotics alone several investigations were performed.
Coamoxiclav increases the phagocytotic activity of PMNs
in vitro tested with un-opsonized and opsonized Staphy-
lococcus aureus [28]. The super oxide formation was
unchanged in this trial. Only very high coamoxiclav con-
centrations (100 mg/l) modestly suppress this function
[28]. In contrast, for ceftriaxone it was shown that the
PMN migration induced by the peptide FMLP (formyl-
methionyl-leucyl-phenylalanine) was suppressed [29].
This was also the case for the phagocytosis of adherent
PMNs but not for PMNs in solution [30]. The respiratory
Table 1: Blood cell parameters
Control G-CSF PCI coamoxiclav coamoxiclav + G-CSF Cef/met Cef/met + G-CSF
WBC (106 cells/ml) 11.7 ± 0.9 22.7 ± 2.0# 8.0 ± 0.7 8.3 ± 0.6 9.6 ± 0.8 8.9 ± 0.7 10.7 ± 2.1
PMN (%) 16 ± 1.6 31 ± 3.5* 34 ± 3.5# 30 ± 4.6§ 26 ± 3.7 37 ± 2.3# 35 ± 1.9#
Blood cell parameters from naive and septic rats. Naive, non-infected control rats, naive rats treated with G-CSF only (20 µg/kg, 12 h before and 12 
h after PCI), PCI rats without prophylaxis, PCI rats with antibiotic prophylaxis (coamoxiclav = CoA or ceftriaxone/metronidazole = Cef/met) and 
PCI rats with antibiotic plus G-CSF prophylaxis were analysed. Blood was sampled 24 h after PCI. Data are presented as means ± SEM from n = 9 
animals/group. ANOVA analysis of variance revealed P < 0.001, df = 6 and post hoc tests of with Bonferroni correction obtained #P < 0.001 versus 
control, *P < 0.01 versus control, §P < 0.05 versus control.BMC Infectious Diseases 2008, 8:55 http://www.biomedcentral.com/1471-2334/8/55
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PMN antimicrobial functions from control (non-infected) and septic rats Figure 2
PMN antimicrobial functions from control (non-infected) and septic rats. Naive, non-infected control rats, naive rats 
treated with G-CSF only (20 µg/kg, 12 h before and 12 h after PCI), PCI rats without prophylaxis, PCI rats with antibiotic 
prophylaxis (coamoxiclav = CoA or ceftriaxone/metronidazole = Cef/met) and PCI rats with antibiotic plus G-CSF prophylaxis 
were analysed. Blood was sampled at 24 h after PCI from n = 9 animals each condition. Migration was assessed with a Boyden 
camber test. Granulocyte superoxid anion formation was determined with a cytochrom-C microplate assay. Data are pre-
sented as mean ± SEM. ANOVA analysis of variance revealed for migration P < 0.05 and for superoxide anion formation P < 
0.001, df = 6 and post hoc tests of with Bonferroni correction obtained *P < 0.01 versus control, **P < 0.001 versus control, 
#P < 0.05 versus PCI, ##P < 0.01 versus PCI, §P < 0.05 versus coamoxiclav.
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burst was unchanged in this group. In vitro metrodinazole
seems to have no influence to the migratory activity,
phagocytosis and the respiratory burst [31,32]. Thus
although ceftriaxone is a potent antibiotic, its effects on
PMN antimicrobial functions are less impressive. The dif-
ference in interaction of G-CSF with the two antibiotics
most probably results from differences in phagocyte activ-
ity, although a direct influence on the antibiotic activity
can not be ruled out.
There is a close interaction of the antimicrobial PMN
functions and the cytokine cascade activated during infec-
tions. In our trial, only the combination of G-CSF and
coamoxiclav decreased systemic TNF-α. In the liver, the
cytokine mRNA expression showed a heterogeneous pic-
ture. TNF-α was also significantly reduced by the combi-
nation coamoxiclav plus G-CSF compared to antibiotic
only. This was not the case with the Cef/met, but in the
group without G-CSF prophylaxis, a lower expression of
TNF-α was observed after Cef/met prophylaxis. IL-1
mRNA levels were not different from control after proph-
ylaxis with coamoxiclav plus G-CSF, but after prophylaxis
with Cef/met plus G-CSF they remained still elevated. The
combinations showed no difference between the two anti-
biotics regarding the cytokines MIP-2 (macrophage
inflammatory protein-2) and IL-10. MIP-2 is a chemokine
predominantly produced by mononuclear leucocytes
which attracts PMNs and IL-10 is a well known anti-
inflammatory cytokine. Surprisingly these two factors
seem to be less important for the different antibiotic effect
in combination with G-CSF, at least as measured in the
liver. We can not exclude that they may play an important
role in other organs or systemically.
Antibiotics have different effects on Cytokines. A recent in
vitro study demonstrated that coamoxiclav reduces mRNA
expression of pro-inflammatory cytokines such as TNF-α,
IL-1, IL-6 from PMNs stimulated with Klebsiella pneumo-
niae; in contrast, expression of the anti-inflammatory
cytokine IL-10 did not increase [1]. In vitro work also dem-
onstrates that TNF-α release is increased by ceftriaxone,
whereas other cytokines including IL-1, IL-6, and IL-8
were unchanged [33,34]. TNF-α is able to enhance the
undirected migration and to prime PMNs for a second
stimulus [35]. Grutoski et al showed that the effect of
TNF-α is much more complex, since TNF-α induces a fac-
tor which suppresses migration and antimicrobial activity
of PMNs in a paracrine manner [36]. Elevated TNF-α lev-
els are regarded to be adverse for the antimicrobial func-
tions of PMNs and consequently for the outcome from
major infections such as sepsis. In contrast G-CSF has
anti-inflammatory properties [37] and the potential to
enhance migration and the oxidative burst in septic
patients [38]. The antibiotic differences have also implica-
tions for the possible clinical use of G-CSF. In a recent ran-
domised clinical trial with a G-CSF prophylaxis for
improvement of the outcome of high risk patients after
colorectal cancer surgery also two different antibiotics
(cefuroxime/metronidazole and ofloxacin/metronida-
zole) were used [39]. In this trial again one antibiotic
(cefuroxime/metronidazole) in combination with G-CSF
was more effective to reduce the complication rate and
length of hospital stay and to improve quality of life. The
effects from cytokines and PMN functions are differen-
tially regulated by antibiotics.
Conclusion
There are substantial differences in the interaction of anti-
biotics with G-CSF. G-CSF was only able to improve sur-
vival in combination with coamoxiclav. Increased survival
may be explained by an improvement of antimicrobial
PMN functions and by an altered cytokine expression
which regulate these functions. Therefore, the selection of
the antibiotic for combination with G-CSF in sepsis treat-
ment should be guided not only by the bacteria to be
eliminated, but also by the effects on antimicrobial func-
tions of PMNs and the cytokine response. The antimicro-
bial activity will be optimised by a positive combination
of direct antibiotic effects and indirect effects of the innate
immune system like the PMNs.
TNF-α protein levels in the plasma 24 hours after PCI Figure 3
TNF-α protein levels in the plasma 24 hours after 
PCI. Naive, non-infected control rats, naive rats treated with 
G-CSF only (20 µg/kg, 12 h before and 12 h after PCI), PCI 
rats without prophylaxis, PCI rats with antibiotic prophylaxis 
(coamoxiclav = CoA or ceftriaxone/metronidazole = Cef/
met) and PCI rats with antibiotic plus G-CSF prophylaxis 
were analysed. Cytokine levels were determined by ELISA. 
ANOVA analysis of variance revealed P < 0.001 for n = 9/
group and post hoc tests of with Bonferroni correction 
obtained a significant increase of the cytokine level in all 
infected animals compared to control (P < 0.01) and *P < 
0.05 versus PCI, **P < 0.01 versus PCI and #P < 0.05 versus 
coamoxiclav. Data are presented as mean ± SEM.
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Cytokine mRNA expression profiles from control and septic rats Figure 4
Cytokine mRNA expression profiles from control and septic rats. Rats were 24 hours after PCI sacrificed, and liver 
probes were analyzed by reverse, semi-quantitative, competitive RT-PCR. Results are shown for the cytokines TNF-α, IL-6, IL-
1, MIP-2 and IL-10. The data are expressed as means + SEM (n = 3 animals each condition). ANOVA analysis of variance 
revealed for the different cytokines P < 0.001, df = 4 and post hoc tests of with Bonferroni correction obtained *P < 0.05 ver-
sus control, **P < 0.01 versus control, #P < 0.05 versus coamoxiclav.
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